Pipeline Overview
Click to learn about the trilaciclib mechanism of action
G1 is advancing two novel therapies for people living with cancer. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
